NYSE:CNMDMedical Equipment
Will Exiting Gastroenterology to Refocus on Core Surgery Change CONMED’s (CNMD) Margin Expansion Narrative?
In early December 2025, Olympus, W. L. Gore & Associates, and CONMED announced that US distribution of the GORE VIABIL biliary stent will shift from CONMED to Olympus on January 1, 2026, as CONMED accelerates the end of its Gore distribution agreement.
At the same time, CONMED confirmed it will exit its gastroenterology product lines to focus resources on minimally invasive, robotic, and orthopedic soft tissue surgery, aligning its portfolio more tightly with its core areas.
Now, we will...